Kukje Pharma Co., Ltd.
Financials
Valuation Metrics
Kukje Pharma Co., Ltd.'s Market Cap is ₩693B. At end of 2025 it was ₩910B. Ranked #1553 of 2,421 in KR market (top 64%), #642 of 781 on KOSPI (top 82%), #172 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 74%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 69.30B KRW | KR#1,553/2,421 Sec#172/231 |
| Revenue | 181.27B KRW | KR#1,083/2,421 Sec#64/231 |
| Net Income | 4.99B KRW | KR#1,210/2,421 Sec#81/231 |
| Total Assets | 185.21B KRW | KR#1,367/2,421 Sec#100/231 |
| Net Assets | 99.37B KRW | KR#1,422/2,421 Sec#113/231 |
| Employees | 256 | KR#912/2,421 Sec#78/231 |
| Value | ||
| P/E | 13.88x | KR#1,004/2,421 Sec#56/231 |
| P/B | 0.70x | KR#1,114/2,421 Sec#60/231 |
| P/S | 0.38x | KR#734/2,421 Sec#23/231 |
| EV/EBITDA | 18.86x | KR#984/2,421 Sec#57/231 |
| FCF Yield | 3.20% | KR#968/2,421 Sec#60/231 |
| Profitability | ||
| ROE | 5.02% | KR#1,094/2,421 Sec#76/231 |
| ROA | 2.70% | KR#1,093/2,421 Sec#80/231 |
| Op. Margin | 2.47% | KR#1,318/2,421 Sec#93/231 |
| Revenue Growth | 8.02% | KR#1,018/2,421 Sec#98/231 |
| Earnings Growth | -21.78% | KR#938/2,421 Sec#59/231 |
| Financial Health | ||
| Debt Ratio | 86.38% | KR#1,423/2,421 Sec#165/231 |
| Total Debt | 30.00B KRW | KR#1,230/2,421 Sec#96/231 |
| FCF | 2.22B KRW | KR#1,066/2,421 Sec#75/231 |
| Cash | 14.91B KRW | KR#1,432/2,421 Sec#112/231 |
| Current Ratio | 1.14x | KR#1,565/2,421 Sec#159/231 |
| Net Debt/EBITDA | 3.37x | KR#929/2,421 Sec#70/231 |
| Dividend | ||
| Div. Yield | 0.91% | KR#1,143/2,421 Sec#67/231 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -28.80% | KR#1,529/2,421 Sec#122/231 |
| 1M Return | 2.66% | KR#963/2,421 Sec#70/231 |
| From 52W High | -40.13% | KR#935/2,421 Sec#63/231 |
| 1Y MDD | -41.78% | KR#649/2,421 Sec#47/231 |
| Trading | ||
| Volume | 14,039 shares | KR#1,770/2,421 Sec#175/231 |
| Trading Value | 46.0M KRW | KR#1,865/2,421 Sec#190/231 |
| Foreign Own. | 3.70% | KR#1,116/2,421 Sec#101/231 |
| Per Share | ||
| EPS | 236 KRW | KR#1,244/2,421 Sec#84/231 |
| BPS | 4,696 KRW | KR#1,539/2,421 Sec#111/231 |
Company Info
Kukje Pharma, established in 1959, is a specialized pharmaceutical manufacturing and sales company, listed on the securities market in 1975, and founded its subsidiary Kukje Care in 2011. It handles both specialized pharmaceuticals, like QRalone Eye Drops, and over-the-counter drugs, supplying products nationwide from its Seongnam headquarters and manufacturing/research facilities in Ansan. The company is actively researching 2 new drugs and 3 modified new drugs, aiming for new drug development and increased sales by developing anti-inflammatory treatments such as indole carboxamide derivatives. Kukje Pharma is headquartered in Seongnam-si, Gyeonggi-do.